CSP
RPRX icon

Cary Street Partners’s Royalty Pharma RPRX Stock Holding History

Cary Street Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,405
Closed -$943K – 1026
2025
Q4 		$943K Buy
24,405
+260
+1% +$9.91K 0.02% 448
2025
Q3 		$852K Buy
24,145
+2,785
+13% +$101K 0.02% 459
2025
Q2 		$770K Buy
21,360
+1,780
+9% +$59K 0.02% 457
2025
Q1 		$610K Buy
+19,580
New +$621K 0.02% 491

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Cary Street Partners's RPRX Position: Q1 2026 in Review

Cary Street Partners sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 24,405 shares — an estimated $943K sold.

Cary Street Partners first reported a position in RPRX in Q1 2025 and held it in 4 quarters. The position peaked at $943K in Q4 2025. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Cary Street Partners reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Cary Street Partners sold 24,405 Royalty Pharma shares in Q1 2026, an estimated $943K.
  • Cary Street Partners first reported a position in Royalty Pharma in Q1 2025 and held it in 4 quarters.
  • Cary Street Partners's Royalty Pharma position peaked at $943K in Q4 2025.
  • 592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Cary Street Partners's 13F filing for Q1 2026, filed 29 Apr 2026.